Pharma sector to top Rs.60,000 crore by ''08

21 Sep 2005

1

New Delhi: Industry body Assocham has said that the Indian pharma industry would grow at 11 per cent to touch Rs60,000 crore in 2007-08 from Rs39,000 crore in 2003-04, when drugs worth US$65bn would go off patent.

Pharmaceutical exports from India would grow at 18 per cent to touch volume of Rs30,000 crore in 2007-08 from Rs15,500 crore during 2003-04, according to a study released by Assocham in New Delhi on Tuesday.

The study also points out that globally drugs worth US$40bn would go off patent this year and another US$70bn dollar would go off patent in 2008. Indian pharma companies would then raise their stake in the world market to 30 per cent, it said.

Indian companies could leverage their strength in terms of low cost of production and availability of quality manpower as domestic production cost was 50 per cent less as compared to developed countries, it said.


Latest articles

China urges Iran to ensure navigation safety in Strait of Hormuz

China urges Iran to ensure navigation safety in Strait of Hormuz

Widebody ambition: El Al expands Boeing 787 fleet to strengthen long-haul strategy

Widebody ambition: El Al expands Boeing 787 fleet to strengthen long-haul strategy

India’s electronics exports to China rise, but Apple-linked surge figures need caution

India’s electronics exports to China rise, but Apple-linked surge figures need caution

Carmakers explore energy storage, but claims of major pivot and write-downs are overstated

Carmakers explore energy storage, but claims of major pivot and write-downs are overstated

Government advances Dholera semiconductor hub, but timelines and scale claims need caution

Government advances Dholera semiconductor hub, but timelines and scale claims need caution

South Korea’s AI chip push grows, but 2nm robotics claims remain premature

South Korea’s AI chip push grows, but 2nm robotics claims remain premature

India–Japan chip collaboration grows, but details around Axiro–EdgeCortix deal remain limited

India–Japan chip collaboration grows, but details around Axiro–EdgeCortix deal remain limited

Post-splashdown: What Artemis II taught us about the ‘deep space wall’

Post-splashdown: What Artemis II taught us about the ‘deep space wall’

Carmakers explore energy storage, but claims around Ford and GM pivot remain overstated

Carmakers explore energy storage, but claims around Ford and GM pivot remain overstated